{"id":2179,"date":"2026-05-28T07:00:30","date_gmt":"2026-05-28T07:00:30","guid":{"rendered":"https:\/\/www.pharglass.com\/?p=2179"},"modified":"2026-05-28T07:12:21","modified_gmt":"2026-05-28T07:12:21","slug":"insulin-pen-injectors-comprehensive-classification-treatment-regimens-and-clinical-best-practices","status":"publish","type":"post","link":"https:\/\/www.pharglass.com\/fr\/insulin-pen-injectors-comprehensive-classification-treatment-regimens-and-clinical-best-practices\/","title":{"rendered":"Insulin Pen Injectors: Comprehensive Classification, Treatment Regimens, and Clinical Best Practices"},"content":{"rendered":"<h2 class=\"wp-block-heading\">From Device Selection to Optimized Glycemic Control \u2014 An Evidence-Based Guide<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Diabetes mellitus affects hundreds of millions worldwide, and insulin therapy remains a cornerstone for type 1 and many type 2 diabetes patients. Among the various delivery methods, <strong>insulin pen injectors<\/strong> have revolutionized self-administration \u2014 offering greater accuracy, convenience, and patient compliance compared to traditional vials and syringes. This article provides a technically rigorous overview of insulin pen classification by function and manufacturer, followed by a detailed breakdown of common insulin pen treatment regimens (30R, 50R, N, R). Healthcare professionals, patients, and digital health content curators will find actionable insights grounded in clinical practice.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Part 1: Classification of Insulin Pens by Functional Use<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Selecting the right insulin pen device is the first step toward reliable dosing. Based on reusability, insulin pens fall into two primary categories.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. Reusable Insulin Pens (Durable Pens)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Reusable insulin pens are designed for long\u2011term use \u2014 often lasting for many years or even a lifetime. The patient inserts a replaceable 3\u202fmL insulin cartridge (typically 300 units). When the cartridge is empty, it is discarded and replaced with a new one, while the pen body is retained.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key characteristics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost\u2011effective over time<\/strong> \u2013 Higher upfront cost but lower recurring expense.<\/li>\n\n\n\n<li><strong>Precise dosing<\/strong> \u2013 Most models offer 1\u2011unit or 0.5\u2011unit increments.<\/li>\n\n\n\n<li><strong>Wide availability<\/strong> \u2013 In many countries (including China), reusable pens are readily available from brands such as Novo Nordisk (NovoPen), Eli Lilly (HumaPen), and Sanofi (ClikSTAR).<\/li>\n\n\n\n<li><strong>Example brands<\/strong> \u2013 Becton Dickinson insulin pen (see manufacturer classification below), NovoPen 6 with memory function.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Disposable Insulin Pens (Prefilled Pens)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Disposable pens come pre\u2011filled with insulin. Once the cartridge is empty (or after a specified number of days in use), the entire pen is discarded. A new pen is required for the next refill.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key characteristics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simple and hygienic<\/strong> \u2013 No need to load cartridges; reduces contamination risk.<\/li>\n\n\n\n<li><strong>Ideal for low\u2011dexterity patients<\/strong> \u2013 Often easier to handle.<\/li>\n\n\n\n<li><strong>Geographic variation<\/strong> \u2013 Common in North America and Europe; less common in China (as noted in the source document).<\/li>\n\n\n\n<li><strong>Example<\/strong> \u2013 FlexPen (Novo Nordisk), SoloStar (Sanofi), KwikPen (Eli Lilly).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical note:<\/strong> While disposable pens offer convenience, they generate more medical waste. For environmentally conscious patients or those using multiple insulin types, reusable pens may be preferable.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Part 2: Classification of Insulin Pens by Manufacturer<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Different manufacturers produce pens with distinct ergonomics, dose dialing mechanisms, and cartridge interfaces. Patients and clinicians must read the device\u2019s instruction manual and receive proper training from diabetes educators before first use.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Fabricant<\/th><th>Representative Pen Model<\/th><th>Caract\u00e9ristiques principales<\/th><\/tr><\/thead><tbody><tr><td><strong>Becton Dickinson (BD)<\/strong><\/td><td>BD Insulin Pen<\/td><td>High\u2011precision dosing; compatible with BD micro\u2011fine needles; reusable design<\/td><\/tr><tr><td><strong>Owen Mumford<\/strong><\/td><td>Autopen (classic model)<\/td><td>Easy\u2011squeeze push\u2011button; available in 1\u2011unit or 2\u2011unit increments; reusable<\/td><\/tr><tr><td><strong>Novo Nordisk<\/strong><\/td><td>NovoPen 6 \/ Echo Plus<\/td><td>Smart pens with memory \/ Bluetooth connectivity; half\u2011unit dosing (Echo)<\/td><\/tr><tr><td><strong>Sanofi<\/strong><\/td><td>ClikSTAR \/ JuniorSTAR<\/td><td>Large dose display; low\u2011force injection; junior version with 0.5\u2011unit steps<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>HumaPen Luxura HD<\/td><td>Half\u2011unit dosing; metal body; durable construction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Important:<\/strong> Insulin cartridges from different brands are <strong>not<\/strong> universally interchangeable. Always match the cartridge brand to the pen type. For example, a NovoPen requires Novo Nordisk 3\u202fmL cartridges.<\/p>\n<\/blockquote>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Part 3: Insulin Pen Treatment Regimens \u2014 Clinical Approaches<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The source document outlines four core regimens based on premixed insulin ratios or single\u2011type insulins. These are widely used in clinical practice, especially in Asia where premixed insulins dominate.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Regimen 1: Premixed Insulin 30R (Most Common)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Insulin composition:<\/strong> 30% short\u2011acting insulin (R) + 70% intermediate\u2011acting insulin (NPH, or N).<br><strong>Typical product name:<\/strong> Novolin 30R, Humulin 30\/70, or generic 30R penfill. Each cartridge contains 300 units.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Injection schedule:<\/strong> Twice daily \u2014 before breakfast and before dinner.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mechanism of action:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Morning dose (2\/3 of total daily dose)<\/strong> \u2013 The 30% short\u2011acting component controls post\u2011breakfast glucose; the 70% NPH covers lunch and afternoon glucose.<\/li>\n\n\n\n<li><strong>Evening dose (1\/3 of total daily dose)<\/strong> \u2013 Short\u2011acting component controls post\u2011dinner glucose; NPH provides basal coverage through the night and early morning.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dose titration:<\/strong> Adjust by <strong>2 units<\/strong> per injection based on self\u2011monitored blood glucose (SMBG) levels. Typically, breakfast dose is twice the dinner dose (e.g., 20 units AM \/ 10 units PM).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Avantages :<\/strong> Simple two\u2011injection regimen; good for patients with predictable meal schedules.<br><strong>Limites :<\/strong> May not provide optimal overnight basal coverage; lunchtime hypoglycemia risk if midday meal is delayed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Regimen 2: Premixed Insulin 50R<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Insulin composition:<\/strong> 50% short\u2011acting (R) + 50% intermediate (NPH).<br><strong>Example product:<\/strong> Novolin 50R (Novo Nordisk).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>When to use:<\/strong> For patients with persistently high postprandial glucose despite 30R therapy. The higher proportion of short\u2011acting insulin (50% vs 30%) provides stronger control of meal\u2011time spikes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Injection schedule:<\/strong> Same twice\u2011daily pattern (breakfast + dinner).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dose distribution:<\/strong> Often also 2\/3 AM, 1\/3 PM, but can be individualized.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Potential drawbacks:<\/strong> Because the intermediate component is only 50% (vs 70% in 30R), coverage for inter\u2011prandial periods (mid\u2011morning, mid\u2011afternoon, and overnight) may be insufficient. Monitor for late\u2011night hypoglycemia or fasting hyperglycemia.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical pearl:<\/strong> 50R is particularly useful in East Asian populations where post\u2011meal glucose excursions tend to be more pronounced.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Regimen 3: Intermediate\u2011Acting Insulin N (NPH) Alone<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Insulin composition:<\/strong> 100% NPH insulin (e.g., Novolin N, Humulin N). No short\u2011acting component.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Indications:<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Add\u2011on to oral agents in type 2 diabetes<\/strong> \u2013 For patients with inadequate basal control, one or two daily NPH injections may be added to metformin or sulfonylureas.<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Example:<\/em> Bedtime NPH to control fasting glucose.<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Combination with a separate short\u2011acting insulin (R)<\/strong> \u2013 The patient uses an NPH pen <strong>et<\/strong> a separate R pen to mimic basal\u2011bolus therapy.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Injection schedule options:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Once daily (bedtime) \u2013 mild fasting hyperglycemia.<\/li>\n\n\n\n<li>Twice daily (breakfast + bedtime) \u2013 more consistent basal coverage.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Limites :<\/strong> NPH has a pronounced peak (4\u20136 hours) and variable absorption. It does <strong>not<\/strong> control meal\u2011related glucose spikes when used alone. Do not use NPH monotherapy for prandial coverage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Regimen 4: Short\u2011Acting Insulin R Alone<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Insulin composition:<\/strong> 100% regular human insulin (e.g., Novolin R, Humulin R). Onset ~30 min, peak 2\u20134 hours, duration ~6\u20138 hours.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Typical use:<\/strong> As part of a basal\u2011bolus regimen \u2014 inject R before each meal (breakfast, lunch, dinner). To cover nocturnal basal needs, patients must either:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Add a bedtime NPH injection, or<\/li>\n\n\n\n<li>Use a separate NPH pen in the morning and evening.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Practical injection schedule (R + NPH combination):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Breakfast: R (covers breakfast)<\/li>\n\n\n\n<li>Lunch: R (covers lunch)<\/li>\n\n\n\n<li>Dinner: R (covers dinner)<\/li>\n\n\n\n<li>Bedtime: NPH (basal coverage overnight)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Important note:<\/strong> Short\u2011acting R must be injected <strong>30 minutes before meals<\/strong> to match glucose rise \u2014 a significant inconvenience compared to rapid\u2011acting analogs (e.g., lispro, aspart). However, R insulin is still widely used in resource\u2011limited settings due to lower cost.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Insulin pen injectors \u2014 whether reusable or disposable, from Becton Dickinson or Owen Mumford \u2014 have transformed diabetes care. Understanding the functional and manufacturer classifications ensures patients select the right device. Equally important, mastering premixed regimens (30R, 50R) and single\u2011insulin regimens (N, R) enables optimal glycemic control. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>For medical professionals: This information is for educational purposes. Individual treatment decisions must be made by qualified practitioners based on patient\u2011specific factors.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Last updated:<\/strong> May 2026<br><strong>Sources:<\/strong> Clinical practice guidelines; manufacturer product information (Novo Nordisk, Eli Lilly, Sanofi, BD, Owen Mumford); diabetes treatment protocols from leading endocrine societies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>From Device Selection to Optimized Glycemic Control \u2014 An Evidence-Based Guide Diabetes mellitus affects hundreds of millions worldwide, and insulin therapy remains a cornerstone for &#8230; <a title=\"Insulin Pen Injectors: Comprehensive Classification, Treatment Regimens, and Clinical Best Practices\" class=\"read-more\" href=\"https:\/\/www.pharglass.com\/fr\/insulin-pen-injectors-comprehensive-classification-treatment-regimens-and-clinical-best-practices\/\" aria-label=\"En savoir plus sur Insulin Pen Injectors: Comprehensive Classification, Treatment Regimens, and Clinical Best Practices\">Lire plus<\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-2179","post","type-post","status-publish","format-standard","hentry","category-technical-insights","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50"],"_links":{"self":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/comments?post=2179"}],"version-history":[{"count":3,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2179\/revisions"}],"predecessor-version":[{"id":2182,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2179\/revisions\/2182"}],"wp:attachment":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/media?parent=2179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/categories?post=2179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/tags?post=2179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}